Human cannabinoid receptor CB2, a G protein-coupled receptor (GPCR) is implicated in an array of health related systemic body functions including the immune response, inflammation, and pain sensing, and it is an important target for pharmaceutical drug development. Structural and functional studies of GPCR by NMR, EPR and fluorescence techniques require non-intrusive, site-specific labeling of the protein. This can be achieved by chemical labeling of cysteines of the receptor. In this study we explored feasibility of labeling of selected cysteines by minimizing the number of reactive SH groups through systematic replacement of the majority of the 13 naturally-occurring cysteines of CB2. The replacement of the six water-exposed cysteines resulted in a well-expressed, fully functional receptor as evidenced by ligand binding- and G protein activation studies. While the replacement of four additional cysteines in the transmembrane domain of the protein lowered ligand binding affinity several fold, the receptor could still be activated by an excess of a high affinity agonists and performed competently in an in vitro G protein activation assay. The reduced cysteine templates of CB2 were either labeled directly or used to introduce new cysteines in selected positions at the extracellular and intracellular surfaces of the protein. The cysteine mutants of CB2 were chemically labeled with 2,2,2-trifluoroethanethiol (TET) and their spectra recorded by 19F NMR in micelles composed of dodecyl maltoside and CHAPS or in particles formed by the NVoy polymer. The latter was advantageous since it yielded monomeric receptor suitable for recording solution-state 19F NMR spectra with decent resolution. This study is a precursor for exploring the structure-function relationship of CB2 by NMR and EPR.
Read full abstract